Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682863 · ClinicalTrials.gov registry record · Phase 3
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
NCT01682863 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 614 participants.
The verdict
NCT01682863, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
Study Summary
This study is to assess the safety and tolerability of two different doses of QVA149 and QAB149 in patients with moderate to severe airflow limitation.
Interventions
- DRUG Placebo
- DRUG QVA149
- DRUG QAB149
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01682863
The ClinicalTrials.gov registry entry for NCT01682863 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01682863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01682863 about?
NCT01682863 is a clinical study titled "A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation". This study is to assess the safety and tolerability of two different doses of QVA149 and QAB149 in patients with moderate to severe airflow limitation.
What is the current status of trial NCT01682863?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2012-10. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01682863?
The interventions under investigation include: Placebo (DRUG), QVA149 (DRUG), QAB149 (DRUG).
Who is sponsoring clinical trial NCT01682863?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.